Pancreatic Cancer Research

ResearcherRoyal Marsden NHS Foundation TrustActive in the last 2 years

David Cunningham

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0001-5158-1069; OpenAlex author ID A5056345420. Sources: ClinicalTrials.gov.

Their work

Papers
26 (first author 1, last author 1)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
0
Collaborators
105
Papers, trials and grants by year

2006: 1 trial · 2007: none · 2008: none · 2009: none · 2010: none · 2011: none · 2012: 1 paper · 2013: 1 paper · 2014: 4 papers · 2015: 3 papers · 2016: 3 papers · 2017: 1 paper · 2018: 3 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: none · 2023: 1 paper · 2024: 2 papers · 2025: 1 paper · 2026: 1 paper

Papers 26

  1. Total Neoadjuvant Approach for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma-UK Tertiary Cancer Centre Experience. Co-author DOI 10.3390/cancers18101597↗
  2. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  3. Surgical Outcomes Following Neoadjuvant Treatment for Locally Advanced and Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/as9.0000000000000486↗
  4. Complete Primary Pathological Response Following Neoadjuvant Treatment and Radical Resection for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers16020452↗
  5. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  6. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  7. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  8. Liposomal Irinotecan + 5-FU/LV in Metastatic Pancreatic Cancer: Subgroup Analyses of Patient, Tumor, and Previous Treatment Characteristics in the Pivotal NAPO… Co-author DOI 10.1097/mpa.0000000000001455↗
  9. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  10. Up-to-Date Tailored Systemic Treatment in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1155/2019/7135437↗
  11. Immunotherapy and pancreatic cancer: unique challenges and potential opportunities. Co-author DOI 10.1177/1758835918816281↗
  12. Identifying the role of neutrophil-to-lymphocyte ratio and platelets-to-lymphocyte ratio as prognostic markers in patients undergoing resection of pancreatic d… Co-author DOI 10.14701/ahbps.2018.22.3.197↗
  13. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  14. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  15. International Association of Pancreatology (IAP)/European Pancreatic Club (EPC) consensus review of guidelines for the treatment of pancreatic cancer. Co-author DOI 10.1016/j.pan.2015.10.013↗
  16. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, rand… Co-author DOI 10.1016/s0140-6736(15)00986-1↗
  17. miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU… First author DOI 10.18632/oncotarget.7208↗
  18. A case of metastatic pancreatic adenocarcinoma with prolonged survival after combination of neoadjuvant FOLFIRINOX therapy and synchronous distal pancreatectom… Co-author DOI 10.1002/jso.23867↗
  19. Management of metastatic pancreatic cancer: Current treatment options and potential new therapeutic targets. Co-author DOI 10.1016/j.critrevonc.2015.03.008↗
  20. Long-term Disease-free Survival Following Combination Multi-visceral and Metastatic Resection with Neoadjuvant FOLFIRINOX for Pancreatic Adenocarcinoma: A Case… Co-author DOI 10.7759/cureus.429↗
  21. The effects of gemcitabine and capecitabine combination chemotherapy and of low-dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patie… Co-author DOI 10.1007/s00262-013-1502-y↗
  22. FOLFIRINOX for locally advanced or metastatic pancreatic ductal adenocarcinoma: the Royal Marsden experience. Co-author DOI 10.1016/j.clcc.2014.09.005↗
  23. The combination of a chemotherapy doublet (gemcitabine and capecitabine) with a biological doublet (bevacizumab and erlotinib) in patients with advanced pancre… Co-author DOI 10.1016/j.ejca.2014.02.003↗
  24. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an … Co-author DOI 10.1016/s1470-2045(14)70236-0↗
  25. Gemcitabine plus capecitabine in unselected patients with advanced pancreatic cancer. Co-author DOI 10.1097/mpa.0b013e31826c6aee↗
  26. A dose escalation study of gemcitabine plus oxaliplatin in combination with imatinib for gemcitabine-refractory advanced pancreatic adenocarcinoma. Last author DOI 10.1093/annonc/mdr317↗

Trials 1

  1. Gemcitabine and Oxaliplatin (Gem-Ox) Plus Glivec in Gemcitabine-refractory Pancreatic Cancer Principal investigator NCT01048320↗

Closest collaborators

The 25 strongest of 105 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Naureen Starling · 8 shared papers, 2012–2026 · strength 0.77
  2. Ricky Harminder Bhogal · 3 shared papers, 2024–2026 · strength 0.74
  3. Kai Tai Derek Yeung · 3 shared papers, 2024–2026 · strength 0.74
  4. John P. Neoptolemos · 9 shared papers, 2014–2025 · strength 0.64
  5. Long R. Jiao · 3 shared papers, 2023–2024 · strength 0.63
  6. Juan W. Valle · 7 shared papers, 2014–2025 · strength 0.55
  7. Ian Chau · 7 shared papers, 2012–2026 · strength 0.54
  8. Paula Ghaneh · 6 shared papers, 2017–2025 · strength 0.54
  9. Christopher Michael Halloran · 6 shared papers, 2017–2025 · strength 0.54
  10. Daniel H. Palmer · 5 shared papers, 2017–2025 · strength 0.48
  11. Thilo Hackert · 5 shared papers, 2017–2025 · strength 0.48
  12. Katharine L. Aitken · 2 shared papers, 2024–2026 · strength 0.46
  13. Paul J. Ross · 5 shared papers, 2014–2025 · strength 0.42
  14. Yuk Ting Ma · 4 shared papers, 2017–2025 · strength 0.39
  15. Harpreet Singh Wasan · 4 shared papers, 2017–2025 · strength 0.39
  16. Bengt L. G. Glimelius · 4 shared papers, 2017–2025 · strength 0.37
  17. Gary Middleton · 5 shared papers, 2014–2025 · strength 0.34
  18. Markus Wolfgang Büchler · 4 shared papers, 2017–2023 · strength 0.32
  19. Christoph Springfeld · 2 shared papers, 2023–2025 · strength 0.29
  20. Olusola Olusesan Faluyi · 3 shared papers, 2017–2025 · strength 0.27
  21. Tim Meyer · 3 shared papers, 2017–2025 · strength 0.27
  22. Pascal R. Hammel · 3 shared papers, 2017–2025 · strength 0.27
  23. David J. Watkins · 5 shared papers, 2012–2021 · strength 0.25
  24. Satvinder Mudan · 3 shared papers, 2015–2018 · strength 0.23
  25. Alan Anthoney · 4 shared papers, 2014–2021 · strength 0.23

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.